|Bid||32.12 x 1000|
|Ask||33.70 x 800|
|Day's Range||33.44 - 33.78|
|52 Week Range||22.01 - 34.14|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||9.47|
|Earnings Date||Apr 27, 2020 - May 03, 2020|
|Forward Dividend & Yield||0.50 (1.49%)|
|Ex-Dividend Date||Feb 06, 2020|
|1y Target Est||37.21|
Canadian Prime Minister Justin Trudeau has canceled his planned trip to Barbados to help resolve widespread rail disruptions caused by indigenous rights activists opposing the construction of a natural gas pipeline, his office said on Sunday. Indigenous communities across Canada have been blocking some key railway lines for nearly two weeks in protest against the Coastal GasLink pipeline in British Columbia, which has forced Canada's biggest railroad, Canadian National Railway Co , to shut operations in eastern Canada.
HONG KONG/BEIJING, Feb 14 (Reuters) - China's ByteDance, the owner of video-sharing app TikTok, will appoint an executive to exclusively lead its nascent gaming business, sources said, signalling its growth ambitions in the sector and an intensifying rivalry with tech giant Tencent. Yan Shou, head of both strategy and gaming businesses, will focus wholly on gaming, as ByteDance sees gaming as the next important source of growth and plans to roll out a game like Honor of Kings, according to one of the people, asking not to be identified because the information isn’t public. ByteDance declined to comment.
(Bloomberg) -- 58 Home, the maid and home-maintenance service owned by China’s Craigslist equivalent 58.com Inc., has delayed its planned U.S. initial public offering, according to people familiar with the matter, as the coronavirus outbreak cripples customer demand.The company’s pre-IPO financing round -- a private fundraising effort that started late last year -- also hasn’t been completed, said the people, who asked not to be named because the information is private. The IPO had been expected to take place in the first half of the year.Shares of 58.com Inc. fell 4.9% in New York trading, the biggest decline since September.The 58 Home’s move adds to the list of IPO setbacks amid the virus outbreak. Restaurant operator Daikiya Group Holdings Ltd. on Wednesday canceled its first-time share sale in Hong Kong, while Chinese biotech firm InnoCare Pharma Ltd. has postponed investor meetings for its planned listing in the financial hub.Read: Virus Hits World’s No.1 IPO Market as Investor Meetings ScrappedThe virus has killed at least 1,355 people in China as of Thursday. People across the nation have been minimizing personal contact for fear of contracting the disease, hurting 58 Home’s on-demand services including part-time cleaners and home handymen.“Obviously, the virus outbreak has affected home and cleaning services -- that entire sector has almost been brought to a standstill,” 58 Home said in a statement. “Our short-term revenue will be affected.”The firm declined to comment on its IPO and fundraising plans.The company added it is facing a severe shortage of maids, and 30 million people in the home and cleaning-services sectors could lose their jobs if the outbreak continues.Workers StrandedMany workers are still stranded in their hometowns, where they traveled for Lunar New Year celebrations, and haven’t been able to return to major cities after the authorities curtailed travel to try to contain the virus.To ensure the health of maids who work on its platform, 58 Home has been logging their travel history, and offering masks and temperature checks.Locally known as 58 Daojia, the company has been seeking funds to bankroll an expansion into China’s competitive online services arena. It was aiming for a valuation of as much as $2 billion in a U.S. IPO.58 Home is one of China’s leaders in helping people connect online with services from flower delivery to home cleaning. Backed by Tencent Holdings Ltd., it’s vying against deeper-pocketed rivals such as Meituan Dianping and businesses operated by e-commerce leader Alibaba Group Holding Ltd. All are targeting a slice of a market for physical, on-demand services that are being disrupted by online technology.58.com’s unit raised its last private funding round in 2015, garnering $300 million from investors including Alibaba, KKR & Co. and Ping An Group. Parent 58.com holds 68.8% of the company’s equity interest but doesn’t consolidate the unit’s financials in its own results, according to its annual filing.(Updates to add 58.com Inc. share price in third paragraph)To contact the reporters on this story: Lulu Yilun Chen in Hong Kong at email@example.com;Dong Cao in Beijing at firstname.lastname@example.orgTo contact the editors responsible for this story: Candice Zachariahs at email@example.com, Peter Vercoe, Fion LiFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Telecom Italia (TIM) is set to pick private equity firm KKR to help it to create a national fibre-optic champion with Open Fiber, two sources familiar with the matter said on Thursday. One of the sources said TIM was close to selecting KKR because the U.S. investment firm had also expressed an interest in investing in the former phone monopoly's secondary network - the part that connects street cabinets to subscribers' homes - which it values at 7.0-7.5 billion euros ($7.6-$8.2 billion). KKR declined to comment.
(Bloomberg) -- Telecom Italia SpA is close to picking the private equity giant KKR & Co. to help it acquire wholesale fiber carrier Open Fiber SpA, according to people familiar with the matter.Telecom Italia is choosing the U.S. investment firm because it’s also open to purchasing a minority stake in a portion of the Italian company’s landline network, the socalled “secondary network” of copper and fiber lines running from street cabinets to premises, that’s valued by KKR at 7 billion euros ($7.6 billion) to 7.5 billion euros, said the people, who asked not to be named because the discussions are private.Telecom Italia shares rose as much as 3.2% at the market open in Milan, their biggest intraday gain since November. The larger goal is building a single national network, an approach favored by the Italian government led by Premier Giuseppe Conte.Since last year, Telecom Italia Chief Executive Officer Luigi Gubitosi has considered enlisting international funds to help finance a potential network deal with rival Open Fiber, people familiar with the matter said at that time. Gubitosi is also looking to boost demand for premium services, work along with rivals on network investments to cut costs, and spin off noncore assets.Open Fiber’s investors include Italy’s state lender Cassa Depositi e Prestiti and the country’s largest utility, Enel SpA. Francesco Starace, CEO of Enel, said last week in an interview with Börsen Zeitung that he isn’t going to sell the company’s stake in Open Fiber. In contrast, Cassa Depositi would be open to selling its Open Fiber stake, another person said.Spokespeople for Telecom Italia and KKR declined to comment. Representatives for Open Fiber and Cassa Depositi weren’t available after business hours.Open Fiber reported full-year 2018 revenue of 114 million euros. Its active customers numbered 500,000 at the end of that year, and the company reached more than 5 million households with its fiber network.(Updates with share price in third paragraph)\--With assistance from Liana Baker.To contact the reporter on this story: Daniele Lepido in Milan at firstname.lastname@example.orgTo contact the editors responsible for this story: Nick Turner at email@example.com;Rebecca Penty at firstname.lastname@example.orgFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Protests broke out in many parts of Canada over the past week, triggered by arrests of dozens of protesters on traditional indigenous land along a route for TC Energy Corp's planned Coastal GasLink pipeline. The demonstrations have disrupted freight and passenger rail and Canadian Prime Minister Justin Trudeau on Wednesday urged protesters to find a quick solution. The flashpoint was police arrests that started last week in northern British Columbia of protesters who oppose the pipeline's construction on traditional land of the Wet'suwet'en indigenous people.
The following are the top stories on the business pages of British newspapers. - U.S. private equity firm KKR & Co Inc has ruled itself out of a bid for NMC Health Plc after the troubled private hospitals group said that it had been approached. - Link Real Estate Investment Trust, which has extensive property investments including shopping centres in China, abandoned talks to support Intu Properties Plc's planned equity raise at the end of this month.
(Bloomberg) -- Barclays Plc had the deal seemingly locked up.Along with a trio of smaller lenders, the bank had agreed to arrange a $1.1 billion loan for ACProducts’ buyout of a unit of rival Masco Corp. While the terms of the financing weren’t quite as good as the kitchen-cabinet maker’s private equity owners had hoped, getting a signed commitment from the banks allowed the company to finally announce the deal in mid-November.Then a couple of months later, something odd happened: a new -- and markedly better -- funding proposal landed in front of the buyout firm’s executives. The terms were so much better, in fact, that they would wind up coming out ahead even though walking away from the Barclays deal would trigger millions of dollars in breakup fees, according to people with knowledge of the matter. They said yes.The last-minute lender wasn’t Bank of America Corp. or JPMorgan Chase & Co. or any of Barclays’ other traditional rivals. It was KKR & Co., a giant in the world of private equity that is normally on the receiving, not giving, end of deals in the $1.2 trillion U.S. leveraged loan market. And the decision to undercut Barclays on the ACProducts loan underscores just how cutthroat KKR and other private-equity firms have become in recent years as they look to play a bigger role in the lending market.Representatives from Barclays, KKR and American Industrial Partners, which owns ACProducts, declined to comment on the transactions.Breakage FeeFor KKR, its credit-investing and debt underwriting business has increasingly put it in competition with established Wall Street players, especially in the business of offering buyout financing. Private capital providers are rushing to build out direct lending operations, looking to capitalize on a shift in global finance many say is just getting started.KKR’s ACProducts deal was especially surprising to market watchers because Barclays already had an established relationship with the company and its sponsor.The bank had lined up about $400 million of financing for a separate acquisition the Texas-based company made about a year ago. While Barclays was forced to take about half of that debt on its balance sheet as syndicated loan buyers balked, the bank had been willing to lend to the company when others wouldn’t. Its M&A advisers also worked with ACProducts on the Masco acquisition.In the end, Barclays didn’t walk away empty handed. In fact, thanks to the so-called alternative-transaction fee, the bank is still getting around half of the money it would have otherwise collected for underwriting the deal -- without having to go out and sell it to investors, one of the people said, asking not to be identified because the details are confidential.The loan arranged by KKR will also repay ACProducts’ existing debt, getting Barclays out of the portion of the original financing it was never able to offload.The KKR package had several advantages over the Barclays-led deal. For starters, it would eliminate the need for a bond, which would have burdened the company with additional disclosures and been more expensive to repay in the event American Industrial Partners wanted to sell the company.It also offered a lower cost of capital compared to the rates at which the banks had agreed to backstop the deal, and didn’t come with the additional investor protections that direct lenders often require, the people said.KKR’s credit division and some co-investors have also agreed to take around three-quarters of the loan themselves, leaving only a small portion of the financing exposed to the ebb and flow of the syndicated market, one of the people said.The unitranche loan maturing in 2025 may pay 6.5 percentage points over the London interbank offered rate and sell at an original issue discount of 99 to 99.5 cents on the dollar. Investors have until Feb. 18 to participate in the offering.(Updates with original issue discount in final paragraph)To contact the reporter on this story: Davide Scigliuzzo in New York at email@example.comTo contact the editors responsible for this story: Natalie Harrison at firstname.lastname@example.org, Boris KorbyFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
NMC Health shares slumped nearly 15% as Kohlberg Kravis Roberts said it's not made a proposal to buy the Middle Eastern hospital operator and that it doesn't intend to make one. GK Investment Holding Group earlier on Tuesday had stated it's in the preliminary stages of considering a bid. NMC, a target of short-seller Muddy Waters, on Monday had said KKR and GK Investment had made "highly preliminary approaches."
Police have arrested 33 people on Monday, ending the closure of Vancouver ports in British Columbia province by indigenous protesters opposing the construction of Coastal GasLink pipeline. The arrests resulted from an injunction granted by a British Columbia court on Sunday to restore access to ports in the city. Port Metro Vancouver is one of Canada's biggest ports and police say protesters received several requests and warnings to clear the area prior to the arrests.
NMC Health PLC said Monday that it has received approaches from Kohlberg Kravis Roberts & Co. and GK Investment Holding Group SA regarding possible offers for the company.
KKR, a leading global investment firm, today announces the signing of an agreement with EQT Infrastructure IV fund ("EQT" or "EQT Infrastructure") and OMERS, for EQT and OMERS to jointly acquire Deutsche Glasfaser ("DG").
Canadian police imposed tighter security limits on Thursday in a remote area of northern British Columbia where indigenous protesters have blocked construction of the Coastal GasLink pipeline. The Union of British Columbia Indian Chiefs said police had started to remove indigenous people from their territories. The C$6.6 billion ($4.97 billion) pipeline, to be operated by TC Energy Corp, will move gas from northeast British Columbia to the Pacific Coast, where the Royal Dutch Shell -led LNG Canada export facility is under construction.
Biotechnology investors seeking companies that target allergy treatments should look no further than Aimmune Therapeutics (NASDAQ:AIMT). The company is working on a drug to treat peanut allergies and if successful, it could change the lives of many.Source: Pavel Kapysh / Shutterstock.com Sure, allergists could treat patients with small doses of peanut flour to induce immunity to the allergen. But after the U.S. Food and Drug Administration approved Palforzia, AIMT stock could soar to new heights. There is currently no other drug company that may catch up to Aimmune.So, what is this biotech company worth and when might investors get rewarded by holding AIMT shares?InvestorPlace - Stock Market News, Stock Advice & Trading Tips Third-Quarter ResultsAimmune earned the FDA's support for using Palforzia in children and teens with peanut allergies in the third quarter. It sent job offers to 80 practice account managers, so investors should expect operating costs leading to losses in the near term. Still, the company ended the period with $200.5 million in cash and cash equivalents. Through a loan agreement with KKR (NYSE:KKR), Aimmune may access another $130 million if needed.Aimmune spent $30.6 million on research and development in the quarter. It lost $1.03 a share. General and administrative expenses were $34 million, up from $21.3 million last year. The higher costs are due to staff hiring. The company is able to sustain near-term losses because it has enough cash on hand. The cash balance suggests that the company will not need to sell shares, which would hurt existing shareholders.The company's revenue will start ramping up now that the FDA approved Palforzia as the first treatment for peanut allergies on Jan. 31. With 1.6 million children and teens allergic to peanuts, the drug will generate strong sales over time. The drug is "a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research."Dosing starts in small quantities, which are then gradually increased. When administered this way, the patient is less likely to have an allergic reaction. The dosing range is 0.5 milligrams to 300 milligrams. Revenue PotentialPalforzia will cost $890 a month, so with 1.6 million potential patients, the addressable market is worth $1.4 billion a month. In reality, the drug may cost as low as $20 a month thanks to a company-offered assistance program. And of course, all of those children and teens with peanut allergies are unlikely to just start taking the drug.On its conference call, Aimmune said the upper price range for the treatment was around $20,000. By comparison, other therapies out there that treat non-life threatening conditions cost $3,500. So, with the current price range, management has the flexibility to adjust pricing depending on demand levels.Aimmune will target around 1,300 allergy clinics, divided into two broad categories. The first group of around 200 to 250 allergists have the experience of treating such patients. The second group is physicians who have an individual practice."… the two segments that make up this 1,300 are only the two segments who essentially are both willing and ready to initiate therapy now. They are largely high throughput skit centers and so their ability to do high volume immunotherapy procedures is already in place," CEO Jayson Dallas said. Valuation on AIMT StockSource: Chart by finbox.ioNine analysts who offer a one-year price target think the stock is worth $50.78. Building on the idea that Aimmune may offer a specialty pharmacy model, investors may estimate its future revenue. As it meets the risk evaluation and mitigation strategy (REMS) requirements, the company may have a fair value of $33.50.Aimmune Therapeutics is a potential growth idea for the long term. The near-term risks are lower after the company gained approval for its allergy drug. As revenue increases, the stock should start to trend higher in 2020.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post Aimmune's Prospects Shine After the FDA Approves Its Allergy Drug appeared first on InvestorPlace.
Rob Salvagno joined Cisco in 1999, just before the dotcom boom went bust, leading its venture activities. He added the title of strategy chief in 2018 when another longtime Cisco exec, Hilton Romanski, joined the Sirus Capital Group private equity firm to set up its Silicon Valley office.
KKR, a leading global investment firm, today announced the appointment of Rob Salvagno as co-head of KKR’s technology growth equity business in the Americas, alongside Jake Heller, an experienced technology investor who joined KKR in New York from Spectrum Equity last year. In Europe, Stephen Shanley will continue to lead the team.
FRANKFURT/DUESSELDORF, Feb 4 (Reuters) - Finland's Kone and private equity firms are battling to buy ThyssenKrupp's prized elevator division worth more than 15 billion euros ($16.6 billion), a deal which would be Europe's biggest private equity deal in 13 years. Thyssenkrupp says it will either list the business, sell either a stake or the business in its entirety as the company aims to cut 12.4 billion euros ($13.7 billion) in debt and pension liabilities. * Kone has submitted a 17 billion euro non-binding bid, including a roughly 3-billion break fee, beating three private equity consortia whose offers were between 15-16 billion.